Delivery Order SPE2DB22D1017-SPE2DB25FG7QA
- Not listed
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Emtricitabine-Tenofovir (200-300mg) in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $3,198.40 and an ultimate completion date of August 22, 2025. The contract was competitively awarded without a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 26, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $2,267.03, is scheduled for completion by July 28, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $2,375.23 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg in quantities of 30 units. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a non-competitive procurement under an existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The U.S. Defense Department's Medical Supply Chain awarded a firm fixed-price delivery order valued at $3,620.08 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Emtricitabine-Tenofovir 200-300 mg tablets in quantities of 30. This non-competitive delivery order, which serves military and federal healthcare systems, represents a single transaction under AmerisourceBergen's larger contract vehicle with the Defense Logistics Agency. The pharmaceutical products will be...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg tablets in a quantity of 30 units. This firm fixed-price delivery order, valued at $1,847.23, represents a non-competitive set-aside award and is scheduled for completion by August 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg tablets in units of 30 with a ceiling value of $2,162.91. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a non-competitive award issued under an existing contract vehicle and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $2,346.16 to AmerisourceBergen Drug Corp for the supply of Emtricitabine-Tenofovir 200-300mg tablets in quantities of 30 units. This non-set-aside, firm fixed-price delivery order was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg in units of 30s, with a ceiling value of $3,142.77 and a firm fixed price structure. This non-set-aside competitive award is categorized as a delivery order under a larger contract vehicle and represents a single transaction within AmerisourceBergen's extensive pharmaceutical distribution portfolio supporting federal...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg tablets in quantities of 30 units, with a ceiling value of $2,235.38. This is a firm fixed-price delivery order with an ultimate completion date of August 15, 2025, representing a single-unit pharmaceutical procurement without set-aside designation. The award was made competitively to AmerisourceBergen Drug Corp, a...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,785.13 with firm fixed pricing and an ultimate completion date of September 9, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG7QADelivery Order
The Defense Logistics Agency awarded a $14,424.27 delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Emtricitabine-Tenofovir 200-300mg units in quantities of 30. The contract represents a firm fixed-price delivery order with an ultimate completion date of July 18, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen fulfills critical pharmaceutical supply requirements for military and veteran healthcare systems through this comprehensive global vehicle. The Emtricitabine-Tenofovir delivery supports the Department of Defense's medical supply chain operations and aligns with DLA's pharmaceutical distribution mission to military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.4k | 7/17/25 |